000 01296 a2200373 4500
005 20250517083927.0
264 0 _c20170523
008 201705s 0 0 eng d
022 _a1468-2060
024 7 _a10.1136/annrheumdis-2016-209166
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDörner, Thomas
245 0 0 _aThe changing landscape of biosimilars in rheumatology.
_h[electronic resource]
260 _bAnnals of the rheumatic diseases
_c06 2016
300 _a974-82 p.
_bdigital
500 _aPublication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
650 0 4 _aAntibodies, Monoclonal
_xeconomics
650 0 4 _aBiosimilar Pharmaceuticals
_xeconomics
650 0 4 _aHumans
650 0 4 _aPharmacovigilance
650 0 4 _aRheumatic Diseases
_xdrug therapy
650 0 4 _aRheumatology
_xtrends
700 1 _aStrand, Vibeke
700 1 _aCornes, Paul
700 1 _aGonçalves, João
700 1 _aGulácsi, László
700 1 _aKay, Jonathan
700 1 _aKvien, Tore K
700 1 _aSmolen, Josef
700 1 _aTanaka, Yoshiya
700 1 _aBurmester, Gerd R
773 0 _tAnnals of the rheumatic diseases
_gvol. 75
_gno. 6
_gp. 974-82
856 4 0 _uhttps://doi.org/10.1136/annrheumdis-2016-209166
_zAvailable from publisher's website
999 _c25815276
_d25815276